6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November, 2019

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number	Description of Exhibits
99.1	Press Release on  Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India dated November 14, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: November 14, 2019	By:	/s/ Sandeep Poddar
		Name:	Sandeep Poddar
		Title:	Company Secretary

EX-99.1

 Exhibit 99.1

	Dr. Reddy’s Laboratories Ltd.
	8-2-337, Road No. 3, Banjara Hills,
	Hyderabad - 500 034, Telangana,
	India.
	CIN : L85195TG1984PLC004507
	Tel      :+91 40 4900 2900
	Fax     :+91 40 4900 2999
	Email :mail@drreddys.com
	www.drreddys.com

November 11, 2019

Corporate Relationship Department	National Stock Exchange of India Ltd.
BSE Limited	“Exchange Plaza”
Dalal Street, Fort	Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001	Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /	Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039	26598238
Scrip Code: 500124	Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on “Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India.”

This is for your information.

With regards,

Sandeep Poddar

Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

	CONTACT
DR. REDDY'S LABORATORIES LTD.	Investor relationS	Media relationS
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.	AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135)	MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40- 49002121)

Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India 

Hyderabad, India, November 14, 2019 For Immediate Release

Hyderabad, India, November 14, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), today announced the entry into the nutrition segment with the launch of its diabetes nutrition drink ‘Celevida’ in India. It’s a first-of-its-kind under Dr. Reddy’s nutrition portfolio and clinically proven to help manage blood glucose levels among Indian patients.

The brand ‘Celevida’ is derived from two words ‘Celebration’ and ‘Vida’*, which means ‘Celebrate Life’. It is available in two flavors – Kesar Elachi and Chocolate, which are taste tested with 300+ diabetics and prediabetics¹.

M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories said, “We are pleased to mark our foray into the nutrition segment with Celevida, which will address unmet nutrition needs of the patients in India. Through this nutrition drink, we continue to work towards making a positive impact on people’s health and quality of life.” 

Dr. Reddy’s Celevida is formulated to have high protein (28-30%), high fiber (12-18%) and slowly digested carbohydrates, which will support in managing the postprandial blood glucose response and satiety². The product contains high amount of plant protein that comes from Soy, Ragi and Gram flours. The product has 20 vitamins and minerals, and ingredient such as Folate, Iron, Magnesium, Pantothenic acid, Riboflavin, Vitamin B12, Vitamin B6 and Vitamin C that would further support in managing tiredness and fatigue³. 

Diabetes is a growing challenge in India with a large diabetic (around 73 million) and pre-diabetes population (around 80 million people) and we are estimated to have world’s largest diabetes population by 2035⁴. What is contributing to the rise of diabetes in the growing population is the changing habits of diet and a sedentary lifestyle. The Indian Council of Medical Research has recommended that, the daily diet of an adult should contain at least 60g of protein and 40g of dietary fibre (based on a 2000 Kcal diet)⁵. 

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to  without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein. 

References: 

1- Nielsen diagnostic report- ‘EVALUATING INITIATIVE PERFORMANCE OF CELEVIDA PROPOSITION’

2- Food and Nutrition Sciences. 2019; 10:937-994.

3- Diabetes; 2019 Jun:68 (Supplement 1) & Bartley SH. What do we call fatigue. In: Simonson E, Weiser PC, editors. Psychological and Physiological Aspects of Work and Fatigue. Springfield, IL: Charles C. Thomas; 1976. pp. 409–414.

4- Diabetes Atlas (internet), 2018 (accessed on 18 April). Available from: http://www.diabetesatlas.org/across-the-globe.html

5- Nutrient requirement and recommended dietary allowances for Indians- National Institute of Nutrition, 2010.

*Vida is in Latin language means Life